DPP-1 Inhibitor (CSPC-2231)

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.

Therapeutic Areas